AKAdva Kochavi

Adva Kochavi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adva Kochavi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Arginine Deprivation of ASS1-Deficient Cancers Drives Mistranslation and Shared Neoepitope Production

    by Remco Nagel, Adva Kochavi, Karine Flem-Karlsen, Mrittika Adhikary, Yali Gal-On, Maria G. Klaoudatou, Julien Champagne, Lorenzo Valcanover, Heyilimu Palashati, Morten M. Nielsen, et al.

    Arginine biosynthesis is frequently suppressed in cancer because of the loss of argininosuccinate synthase 1 (ASS1) expression, rendering cancer cells reliant on extracellular arginine. This feature has driven the development of systemic arginine-depleting strategies, which are clinically safe but offer limited clinical benefit. In this study, we demonstrated that under arginine scarcity, cancer cells with low ASS1 expression resort to aberrant mRNA translation, characterized by ribosomal frameshifts and amino acid misincorporations. Although aberrant proteins originated from most arginine codons, the predominant effect was observed at AGA. This codon preference was caused by a selective decrease in tRNAArg (UCU) levels following arginine deprivation, linked to methyltransferase-like 1 (METTL1)–mediated tRNA modification. Proteomics and immunopeptidomics analyses validated that arginine shortage induced aberrant protein production at the endogenous level. T-cell receptor (TCR) T cells that specifically recognize these HLA-presented mistranslated peptides efficiently killed cancer cells after arginine deprivation. These results lay the foundation for improved cancer therapies by combining systemic arginine-depleting strategies with TCR-based targeting of nonclassical neoantigens. Significance: Aberrant protein production induced by arginine deprivation in ASS1-low cancers leads to production of neoantigens that represent promising targets for TCR-T cell therapies.


  • Top Cited Papers

    DNA damage induces p53-independent apoptosis through ribosome stalling

    by Nicolaas J. Boon, Rafaela A. Oliveira, Pierré-René Körner, Adva Kochavi, Sander Mertens, Yuval Malka, Rhianne Voogd, Suzanne E. M. van der Horst, Maarten A. Huismans, Lidwien P. Smabers, et al.

    In response to excessive DNA damage, human cells can activate p53 to induce apoptosis. Cells lacking p53 can still undergo apoptosis upon DNA damage, yet the responsible pathways are unknown. We observed that p53-independent apoptosis in response to DNA damage coincided with translation inhibition, which was characterized by ribosome stalling on rare leucine-encoding UUA codons and globally curtailed translation initiation. A genetic screen identified the transfer RNAse SLFN11 and the kinase GCN2 as factors required for UUA stalling and global translation inhibition, respectively. Stalled ribosomes activated a ribotoxic stress signal conveyed by the ribosome sensor ZAKα to the apoptosis machinery. These results provide an explanation for the frequent inactivation of SLFN11 in chemotherapy-unresponsive tumors and highlight ribosome stalling as a signaling event affecting cell fate in response to DNA damage.